Literature DB >> 15777889

Radiofrequency ablation for malignant liver tumor.

Kelvin K Ng1, Ronnie T Poon.   

Abstract

Radiofrequency ablation (RFA) has been widely practiced to treat unresectable malignant liver tumors. It has the merits of localized tumor ablation and preservation of maximal normal liver parenchyma. In recent years, there has been a tremendous expansion in the application of RFA for patients with malignant liver tumors. However, the therapeutic effect of this local ablation treatment needs to be balanced against its risks and possible local failure. This review focuses on the current status of RFA for malignant liver tumors, with special attention to the indication, approaches, complications, survival benefits, combination therapies, and comparison with other treatment modalities. Although the results of most clinical studies of RFA seem favorable, the associated risks and tumor recurrence should not be underestimated. Careful patient selection, meticulous RFA techniques, and prompt treatment of residual and recurrent tumors are necessary to ensure a better outcome after RFA. Until recently, there has been no strong evidence showing that RFA can replace any other treatment modalities in the management of liver tumors. Nonetheless, more convincing evidence by randomized trials is required for the establishment of a treatment protocol of RFA for patients with malignant liver tumors.

Entities:  

Mesh:

Year:  2005        PMID: 15777889     DOI: 10.1016/j.suronc.2005.01.001

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  17 in total

1.  CT-guided radiofrequency ablation as a salvage treatment of colorectal cancer hepatic metastases developing after hepatectomy.

Authors:  Constantinos T Sofocleous; Elena N Petre; Mithat Gonen; Karen T Brown; Stephen B Solomon; Anne M Covey; William Alago; Lynn A Brody; Raymond H Thornton; Michael D'Angelica; Yuman Fong; Nancy E Kemeny
Journal:  J Vasc Interv Radiol       Date:  2011-04-22       Impact factor: 3.464

2.  Potential of Radiofrequency Ablation in Combination with Immunotherapy in the Treatment of Hepatocellular Carcinoma.

Authors:  Guangfu Li; Kevin F Staveley-O'Carroll; Eric T Kimchi
Journal:  J Clin Trials       Date:  2016-04-05

3.  Long-term survival following radiofrequency ablation of colorectal liver metastases: A retrospective study.

Authors:  Simeon Niyi Babawale; Thomas Mandøe Jensen; Jens Brøndum Frøkjær
Journal:  World J Gastrointest Surg       Date:  2015-03-27

4.  Combined resection and radiofrequency ablation for multifocal hepatocellular carcinoma: prognosis and outcomes.

Authors:  Tan To Cheung; Kelvin K Ng; Kenneth S Chok; See Ching Chan; Ronnie T Poon; Chung Mau Lo; Sheung Tat Fan
Journal:  World J Gastroenterol       Date:  2010-06-28       Impact factor: 5.742

5.  Radiofrequency ablation of lymphoma.

Authors:  Deepak Sudheendra; Mara M Barth; Upendra Hegde; Wyndham H Wilson; Bradford J Wood
Journal:  Blood       Date:  2005-10-27       Impact factor: 22.113

6.  Initial experiences with MR Image-guided laparoscopic microwave coagulation therapy for hepatic tumors.

Authors:  Koichiro Murakami; Shigeyuki Naka; Hisanori Shiomi; Hiroya Akabori; Yoshimasa Kurumi; Shigehiro Morikawa; Tohru Tani
Journal:  Surg Today       Date:  2014-10-09       Impact factor: 2.549

7.  Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma.

Authors:  Kelvin K Ng; Ronnie T Poon; Chung-Mau Lo; Jimmy Yuen; Wai Kuen Tso; Sheung-Tat Fan
Journal:  J Gastrointest Surg       Date:  2007-09-15       Impact factor: 3.452

8.  Management of hepatic metastases from colorectal cancer.

Authors:  Ketan R Sheth; Bryan M Clary
Journal:  Clin Colon Rectal Surg       Date:  2005-08

9.  Percutaneous radiofrequency ablation versus surgical radiofrequency ablation for malignant liver tumours: the long-term results.

Authors:  John Wong; Kit-Fai Lee; Simon Chun-Ho Yu; Paul Sing-Fun Lee; Yue-Sun Cheung; Ching-Ning Chong; Philip Ching-Tak Ip; Paul Bo-San Lai
Journal:  HPB (Oxford)       Date:  2012-11-28       Impact factor: 3.647

10.  A cost-utility analysis of treatments for malignant liver tumours: a pilot project.

Authors:  Andrew McKay; Trish Kutnikoff; Mark Taylor
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.